Wake-up stroke, defined as the situation where a patient awakens with stroke symptoms that were not present prior to falling asleep, represents roughly 1 in 5 acute ischemic strokes and remains a therapeutic dilemma. Patients with wake-up stroke were excluded from most ischemic stroke treatment trials and are often not eligible for acute reperfusion therapy in clinical practice, leading to poor outcomes. Studies of neuroimaging with standard noncontrast computed tomography (CT), magnetic resonance imaging (MRI), and multimodal perfusion-based CT and MRI suggest wake-up stroke may occur shortly before awakening and may assist in selecting patients for acute reperfusion therapies. Pilot studies of wake-up stroke treatment based on these neuroimaging features are promising but have limited generalizability. Ongoing randomized treatment trials using neuroimaging-based patient selection may identify a subset of patients with wake-up stroke that can safely benefit from acute reperfusion therapies.
Introduction Definition
Acute stroke evaluation and management is fundamentally predicated on time from symptom onset. 1, 2 Intravenous tissue plasminogen activator (tPA) remains the only Food and Drug Administration (FDA)-approved nonsurgical reperfusion therapy for acute stroke with evidence-based efficacy, and welldesigned, adequately powered studies have consistently shown that efficacy is exquisitely time sensitive. [3] [4] [5] [6] [7] That being the case, knowledge of the exact time of symptom onset, or at least the time at which the patient was last known to be normal, is paramount.
Patients who go to sleep normal and awaken with stroke symptoms, a phenomenon known as ''wake-up stroke,'' present a management dilemma for acute stroke providers. Sometimes the period of sleep is short and a patient can still be eligible for tPA based on standard time-based criteria; however, when the time at which the patient was last known to be normal is the night prior to a morning presentation, which is often the case, the acute stroke provider is left without the key time-based data by which one typically makes safe therapeutic decisions for tPA candidacy. This makes for a diagnostic and therapeutic ''gray area'' in acute stroke practice.
Epidemiology
The wake-up stroke phenomenon is common. Numerous studies of various size and methodological strength through the years have given a sense of actual incidence of wake-up stroke as compared to other stroke presentations. These mostly stroke-registry-based studies range in estimation of wake-up stroke incidence from 8% in California 8 to 33% in a region of France 9 to nearly 39% in Ohio 10 but most typically suggest somewhere in between 15% and 25%. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Clinical and radiographic characteristics distinguishing wake-up stroke from other modes of stroke onset have been sought, but results have been conflicting. Some older studies have suggested that wake-up strokes seem to be more severe at onset 14, 19 and portend a worse outcome overall, 17, 19 while others suggested there are no appreciable clinical or radiographic differences between wake-up and ''while awake'' strokes. 16, 22, [25] [26] [27] The best estimate of wake-up stroke prevalence comes from a retrospective population-based study of 1854 acute ischemic strokes in the Greater Cincinnati/Northern Kentucky region. In this representative biracial sample, 273 (14.3%) of acute strokes were wake-up strokes, resulting in an adjusted event rate of 26.0/100 000. No clinically significant differences in baseline characteristics were observed between wake-up and nonwake-up strokes; however, patients with wake-up stroke were older (72.3 vs 70.0 years, P ¼ .01) and had higher baseline retrospectively calculated National Institutes of Health Stroke Scale (NIHSS) scores (4 vs 3, P ¼ .004). Importantly, 98 (35%) patients were otherwise eligible for tPA if time was not a factor. 27 Overall, in spite of the methodological heterogeneity and different focus of published studies, the common theme is that wake-up stroke is not rare and the clinical features suggest that there is a place for therapeutic optimism; although, no definitive clinical or radiographic paradigm has yet been established to select wake-up stroke candidates for safe and efficacious reperfusion therapy ( Table 1 ).
Pathophysiologic Hypotheses
The wake-up stroke phenomenon is incompletely understood pathophysiologically. What seems clear, though, is that wake-up strokes are not actuarial quirks of evenly spread stroke risk through the course of a day but likely the result of circadian changes in coagulability, serum catecholamine levels, and autonomic tone. Much like cardiac events, 30 there is a preponderance of strokes of all subtypes in the morning as compared to evening onset. 11, 31 Several homeostatic and structural factors may contribute to this phenomenon. Proposed factors include sleep-disordered breathing with or without patent foramen ovale, [32] [33] [34] overnight changes in autonomic tone affecting blood pressure with morning surges, 35, 36 morning increases in platelet aggregation 37, 38 relatively refractory to clopidogrel, 39 endothelial dysfunction, 40 blood viscosity, 41 and fluctuating prothrombotic/fibrinolytic factor level balance. [42] [43] [44] The circadian blood pressure-related changes behind the morning ''surges,'' which essentially mirror stroke incidence through the course of a day, are a tempting therapeutic target. Given the preponderance of strokes of all types between 0600 and 1200, 31 a treatment trial targeting morning blood pressure changes did not change the distribution of strokes through the course of a day. 45 Lending credence to the contribution of overnight paroxysms of atrial fibrillation, 46 a recent study demonstrated a significant association between wake-up stroke and a new diagnosis of atrial fibrillation. 47 Given the heterogeneity of wake-up stroke subtypes, it is likely that no one factor underlies wake-up stroke but some combination of the aforementioned and other yet undiscovered contributors ( Table 2 ).
Neuroimaging and Wake-Up Stroke
The key feature of wake-up stroke that makes it a therapeutic dilemma is the absence of distinct time of symptom onset, which limits the ability to establish eligibility for acute reperfusion therapies. Diagnostic neuroimaging in a patient with wake-up stroke thereby plays an even stronger role than usual in acute stroke evaluations. Several studies have been conducted to evaluate neuroimaging modalities as a surrogate marker of cerebral ischemia and the so-called ''tissue clock'' to supplant the absent time of onset that starts the strictly clinical ''time clock.'' Several noncontrast computed tomography (CT)-based studies compared early ischemic changes on CT between wake-up stroke and stroke of known onset. Overall, there was no significant difference in early CT changes between wakeup stroke and stroke of known onset within 3 hours 25,28 or 6 hours. 26 These results suggest that the ischemic insult may occur shortly before or at the time of awakening in the absence of early ischemic change.
Perfusion and volume-based imaging with magnetic resonance (MR) or CT-based studies provide more granular physiologic data than noncontrast CT for acute stroke (see Table 3 ). These advanced neuroimaging techniques estimate the volume of brain tissue potentially at risk for progression to infarction (ie, ischemic penumbra) if recanalization does not occur. The volumetric difference between a surrogate for established infarction and penumbra, if present, is referred to as a ''mismatch'' and represents a rational biomarker for treatment selection (see Figure 1 ). Studies of advanced neuroimaging techniques have been conducted in patients with wake-up stroke. An MR-based study of diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI), imaging surrogates of ischemic, and ''at-risk'' tissue, respectively, found that patients with wake-up stroke and stroke of known onset had similar DWI and PWI lesion volumes as well as a similarly high proportion of DWI-PWI mismatch. 52 A similarly designed CT-based study of mismatch between cerebral blood volume (like DWI, the estimate of infarcted tissue) and cerebral blood flow (like PWI, the at-risk tissue) found no difference between the percentage of mismatch between patients with wake-up stroke and stroke of known onset within a therapeutic window. 20 Another interesting mismatch approach utilizes DWI and fluid attenuated inversion recovery (FLAIR) sequences of magnetic resonance imaging (MRI) to identify infarcted versus at-risk tissue. Both sequences detect cerebral water changes but in different time sequences (see Figure 2 ). The DWI sequence is very sensitive to early cerebral water changes; however, the abnormalities noted do not change once they appear after the first several minutes of ischemia, so exact timing of an ischemic injury cannot be made with DWI. The T2-based FLAIR sequence measures the accumulation of cerebral edema as the infarction process proceeds. Thus, in principle, the presence of a DWI lesion and absence of a matched FLAIR abnormality should represent a relatively early infarct. This idea has been studied in several single-center 51,53-56 pilots and a multicenter investigation. 57 Overall, the DWI-FLAIR mismatch was found to very accurately identify ischemic tissue beyond 3 to 6 hours and can identify ischemia within the 3-to 4.5-hour window with excellent specificity. The large multicenter study of 543 patients supported the findings of the single-center studies, with DWI-FLAIR mismatch identified in patients within 4.5 hours of stroke onset with a sensitivity of only 62% but a good specificity of 81%, although interrater agreement was less than ideal (k ¼ .569). A recent publication sought to increase interrater reliability of DWI-FLAIR mismatch identification by color-coding FLAIR intensity and did just that with a roughly 10% increase in positive predictive value for both observers (85%-95% in one and 72%-82% in the other) once color coding was introduced. 58 A recent small observational study noted a DWI-FLAIR mismatch in 44% of their patients with wake-up stroke. 52 These findings supported the initiation of thrombolysis treatment trials based on the identification of a DWI-FLAIR mismatch, which are ongoing and will be discussed further in a subsequent section. Emergent neuroimaging is of heightened importance in the setting of wake-up stroke, given the absence of a clear time of symptom onset. Imaging modalities as simple and rapid as noncontrast CT and as sophisticated as multimodal 
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CT and MRI show promise in identifying patients with acute ischemic stroke who may benefit from systemic thrombolysis. Ongoing randomized treatment trials based on these neuroimaging findings have practice-changing implications.
Treatment Evidence
Currently, there is a lack of a high-level evidence base to support any acute treatment in the setting of wake-up stroke. In the absence of high-level data, there are now many small studies of off-label use of acute reperfusion therapies for wake-up stroke employing various clinical and neuroimaging criteria for inclusion. The majority of studies conducted so far are small, single-center observational studies of off-label intravenous tPA with or without endovascular reperfusion therapies. 29, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] Largermulticenter studies, 76 organized phase II studies, 77 and randomized placebo-controlled treatment trials [78] [79] [80] are fewer in number. Of note, the only large, multicenter, randomized placebo-controlled trial studied a glycoprotein IIb/IIIa inhibitor (abciximab) as an adjunct to intravenous tPA and patients with wake-up stroke made up only a small subgroup of the cohort. The individual CBV-total volume of blood in a given volume of brain (mL/100 g) CBF-total volume of blood moving through a given volume of brain (mL/100 g)
MTT-the average transit time of blood through a brain region TTP-time from contrast arrival-to-peak-intensity flow through a brain region Screen for infarct/penumbra mismatch (see Figure 1 )
Time to ischemic change: variable, depends on patient hemodynamics and CBV threshold for ''infarct,'' but is typically abnormal before clear signs on noncontrast CT MRI Routine MRI Screen for infarct volume, DWI/FLAIR mismatch (see Figure 2 ) characteristics and levels of evidence are detailed in Table 4 . Their inherently biased study designs, small numbers, and marked heterogeneity in inclusion criteria and reported results do not allow for much to be said about acute reperfusion therapy for wake-up stroke other than there seems to be a case for therapeutic optimism and large, randomized, placebo-and sham-controlled studies are justified. Ongoing trials include Efficacy and Safety of MRI-based thrombolysis in Wake Up Stroke (WAKE-UP), 81, 82 THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS), 83 Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND), 84 88 and Wake Up Symptomatic Stroke in Acute Brain Ischemia (WASSABI; Table 5 ). 89 
What to do With Wake-Up Stroke Evaluation
Based on the studies mentioned previously and our own clinical experience, we recommend a wake-up stroke evaluation proceeds as any other acute stroke assessment, with as much clinical detail as possible, an NIHSS examination and basic laboratory studies according to guidelines. This should be followed by multiparametric CT or MRI with noninvasive angiography or fast-track neurosonology (eg, transcranial Doppler and carotid duplex ultrasonography) [90] [91] [92] [93] [94] to screen for an infarction/at-risk mismatch and large arterial occlusion, respectively. Even if one is uncomfortable providing treatment recommendations based on the results given the lack of high-level supporting evidence, the diagnostics can serve to inform prognostication.
Treatment
Regarding treatment of wake-up stroke, the authors agree with the sentiment of the recent systematic review of treatment strategies in wake-up stroke 95 that routine treatment of wake-up stroke cannot be offered based on available evidence. Readers are encouraged to participate in clinical trials so that Table 3 ) and clearly involve much more of the left hemisphere than the CBV map. This discordance is referred to as a multimodal CT mismatch or ''penumbra'' and may represent tissue at risk of infarction but potentially salvageable by reperfusion therapy. Siemens SOMATOM, syngo perfusion software. CT indicates computed tomography. Figure 2 . The DWI/FLAIR mismatch. These 2 axial images of the brain at a level just above the lateral ventricles represent the socalled DWI/FLAIR mismatch that can be seen in the early hours after symptom onset when DWI (left) hyperintensity-which can arise in minutes from symptom onset-occurs in the absence of T2-based FLAIR (right) hyperintensity, which takes 3 to 6 hours to develop. DWI indicates diffusion-weighted imaging; FLAIR, fluid attenuated inversion recovery. we as stroke providers may know how best to treat our patients with wake-up stroke ( Table 6) .
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